Overview

Clinical Estradiol Trial in Women With Schizophrenia

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
To investigate the 'estrogen-protection' hypothesis by comparing changes in psychotic symptoms between one group of patients receiving standard antipsychotic drug treatment plus placebo and a second matched group receiving standard antipsychotic drug treatment plus 100microgram estradiol patch in a double blind controlled trial. Hypothesis : That the women receiving adjunctive estradiol will demonstrate a more rapid and more substantial decrease in psychotic symptoms over the course of the study than the women receiving adjunctive placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Bayside Health
Collaborators:
National Alliance for Research on Schizophrenia and Depression
National Health and Medical Research Council, Australia
Stanley Medical Research Institute
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate